Twist Bioscience Stock Declines as Q3 Earnings Miss Overshadows Revenue Beat

Twist Bioscience (NASDAQ: TWST) shares fell in pre-market trading after the company reported mixed fiscal third-quarter results, with an earnings miss drawing more investor attention than a solid revenue beat.

Shares of the company were down 4.2% in pre-open trading following the announcement.

Quarterly Performance

The synthetic biology company disclosed its financial results for the quarter, presenting a split picture for investors. While revenue showed continued growth, profitability fell short of market expectations.

• Revenue: $118.4 million, beating the analyst consensus estimate of $114.54 million.
• Earnings Per Share (EPS): A net loss of $0.56, which was wider than the consensus forecast for a loss of $0.48 per share.

Investor Focus on Profitability

Ad

The market's negative reaction highlights investor concern over the company's path to profitability. This marks the third consecutive quarter that Twist Bioscience has missed EPS estimates, following similar shortfalls in the first and second quarters of its 2026 fiscal year.

The persistent gap between strong top-line growth and bottom-line performance appears to be frustrating investors. The pre-market decline suggests that the revenue beat was not enough to offset concerns about the company's widening losses.

Context and Analyst Sentiment

Analyst sentiment was mixed heading into the earnings report. Earlier in July, Evercore ISI had downgraded the stock to In Line from Outperform. In contrast, Leerink and Canaccord had raised their price targets on the company during the same month.

The absence of any positive revisions to earnings estimates in the 90 days preceding the report signaled that analysts were already cautious about the company's bottom-line trajectory. Despite the recent decline, the stock remains significantly above its 52-week low of $23.30 after a sharp rally over the past year.